The short-acting insulin market involves the production and manufacturing of fast-acting insulin medication. Short-acting insulin helps regulate blood sugar levels by mimicking the action of natural insulin in the body. It works within 15 minutes of administration and has a shorter duration of action of around 3-5 hours. These properties make short-acting insulin effective for managing post-meal blood sugar spikes. The growing burden of diabetes worldwide, especially type 1 diabetes requiring insulin injections, is a major driver of demand. According to reports, more than 60% of adults aged over 65 years suffer from diabetes in developed nations. As life expectancy increases globally, the prevalence of diabetes in the geriatric population will push the need for effective glucose control via short-acting insulin therapies.

 
The short-acting insulin market is estimated to be valued at USD 9.5 Bn in 2024 and is expected to reach USD 13.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2031.
Key players operating in the short-acting insulin market are Novo Nordisk, Sanofi, Eli Lilly, Wockhardt, Biocon.
Rising incidence of diabetes globally is a major factor fueling demand for short-acting insulin. According to International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021 worldwide.
Technological advancements in drug delivery methods such as insulin pens and pumps have improved convenience and compliance for patients. Short-Acting Insulin Market  with continuous glucose monitoring help achieve tighter glucose control.
Market Trends
- Growing popularity of fast-acting insulin analogs - Insulin lispro, insulin aspart, and insulin glulisine are becoming preferred over regular human insulin due to quicker onset and improved post-prandial glycemic control.
- Combination insulins gaining traction - Premixed insulins combining short and long-acting components in single formulation improve compliance for type 2 diabetes patients.
Market Opportunities
- Expanding patient pool in emerging nations presents significant growth prospect. Countries like China, India, Brazil, Mexico will be key contributors.
- Advent of artificial pancreas technology utilizing automated insulin delivery based on real-time glucose monitoring can revolutionize diabetes management.
Short-Acting Insulin Market Impact of COVID-19
The COVID-19 pandemic has adversely impacted the growth of the global short-acting insulin market. The outbreak led to strict lockdowns and social distancing norms across various countries resulting in limited access to non-essential medical services like diabetes care. This restricted the supply of insulin and other diabetes management medicines. It also negatively affected the demand as many patients postponed their doctor visits and insulin prescriptions owing to the fear of virus exposure and priority given to critical COVID-19 patients. However, as restrictions are gradually lifted post widespread vaccination drives, the market isprojected to recover at a steady pace. Key players are focusing on ensuring uninterrupted supply of insulin via online channels and collaboration with pharmacies. Telehealth and remote monitoring solutions are also being used more extensively to provide diabetes care and support to patients during such crisis situations.
The North American region accounts for the major share in terms of value in the global short-acting insulin market. This is mainly attributed to the growing prevalence of diabetes, strong healthcare infrastructure, rise inadoption of advanced insulin delivery devices, and presence of prominent market players in the region. The high obesity ratesand sedentary lifestyle among people have significantly contributed to the diabetes burden in North America.On the other hand, Asia Pacific is expected to exhibit the fastest growth over the forecast period owing to the large diabetes population, increasing healthcare expenditure, growing awareness about diabetes management and rising income levels in emerging economies like China and India. The region provides lucrative opportunities for manufacturers to expand their customer base.

Get more insights on - Short-Acting Insulin Market

Get this Report in Japanese Language: 速効型インスリン市場

Get this Report in Korean Language:  단기 작용 인슐린 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)